Additional file 1 of Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA5m chelators
Creators: name: Euy Sung Moon
name: Elvas, Filipe
name: Vliegen, Gwendolyn
name: Lombaerde, Stef De
name: Vangestel, Christel
name: Bruycker, Sven De
name: Bracke, An
name: Eppard, Elisabeth
name: Greifenstein, Lukas
name: Klasen, Benedikt
name: Kramer, Vasko
name: Staelens, Steven
name: Meester, Ingrid De
name: Veken, Pieter Van Der
name: Rösch, Frank
Publisher: name: figshare
Year: 2020
Subjects: subject: Biophysics
subject: Biochemistry
subject: Pharmacology
subject: 59999 Environmental Sciences not elsewhere classified
subject: FOS: Earth and related environmental sciences
subject: FOS: Earth and related environmental sciences
subject: 39999 Chemical Sciences not elsewhere classified
subject: FOS: Chemical sciences
subject: FOS: Chemical sciences
subject: Sociology
subject: FOS: Sociology
subject: FOS: Sociology
subject: Immunology
subject: FOS: Clinical medicine
subject: FOS: Clinical medicine
subject: 69999 Biological Sciences not elsewhere classified
subject: FOS: Biological sciences
subject: FOS: Biological sciences

description: Additional file 1: Figure S1. HPLC spectra of DOTA.SA.FAPi with linear gradient condition of 5–95% MeCN (+ 0.1% TFA)/95–5% Water (+ 0.1% TFA) in 10 min, 1 mL/min, tR = 8.6 min. Figure S2. HPLC spectra of DATA5m.SA.FAPi with linear gradient condition of 5–95% MeCN (+ 0.1% TFA)/95–5% Water (+ 0.1% TFA) in 10 min, 1 mL/min, tR = 8.5 min. Figure S3. radiolabeling kinetics at different temperatures of [68Ga]Ga-DOTA.SA.FAPi complex. Figure S4. Stability studies for [68Ga]Ga-DOTA.SA.FAPi complex in human serum, Ethanol and 0.9% isotone NaCl-solution in % of intact conjugate at different time points. Figure S5. Stability studies for [68Ga]Ga-DOTA.SA.FAPi complex against transmetallation (Fe, Cu, Mg and Ca) in % of intact conjugate at different time points. Figure S6. Stability studies for [68Ga]Ga-DOTA.SA.FAPi complex against transchelation (DTPA and EDTA) in % of intact conjugate at different time points. Figure S7. Stability studies for [68Ga]Ga-DATA5m.SA.FAPi complex in human serum, Ethanol and 0.9% isotone NaCl-solution in % of intact conjugate at different time points. Figure S8. radio-HPLC spectra of DOTA.SA.FAPi with linear gradient condition of 5–95% MeCN (+ 0.1% TFA)/95–5% Water (+ 0.1% TFA) in 8 min, 1 mL/min, tR = 9.1 min. Figure S9. Inhibition assay graph and calculated IC50-data for DOTA.SA.FAPi (n = 3) with regard to FAP. Figure S10. Inhibition assay graph and calculated IC50-data for natGa-DOTA.SA.FAPi (n = 3) with regard to FAP. Figure S11. Inhibition assay graph and calculated IC50-data for natLu-DOTA.SA.FAPi (n = 3) with regard to FAP. Figure S12. Inhibition assay graph and calculated IC50-data for DOTA.SA.FAPi (n = 3) with regard to PREP. Figure S13. Inhibition assay graph and calculated IC50-data for natGa-DOTA.SA.FAPi (n = 3) with regard to PREP. Figure S14. Inhibition assay graph and calculated IC50-data for natLu-DOTA.SA.FAPi (n = 3) with regard to PREP. Figure S15. Inhibition assay graph and calculated IC50-data for DATA5m.SA.FAPi (n = 3) with regard to FAP. Figure S16. Inhibition assay graph and calculated IC50-data for natGa- DATA5m.SA.FAPi (n = 3) with regard to FAP. Figure S17. Inhibition assay graph and calculated IC50-data for DATA5m.SA.FAPi (n = 3) with regard to PREP. Figure S18. Inhibition assay graph and calculated IC50-data for natGa-DATA5m.SA.FAPi (n = 3) with regard to PREP. Table S1. Ex vivo biodistribuion data of [68Ga]Ga-DOTA.SA.FAPi at 1 h p.i. (N = 3).